🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6 results for “Stemline Therapeutics B.V.” Clear

  1. Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  2. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  3. ORSERDU 86 mg film-coated tablets, ABEMACICLIB, ABEMACICLIB, ORSERDU 345 mg film-coated tablets, ABEMACICLIB

    Stemline Therapeutics B.V.

    Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  4. ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Stemline Therapeutics B.V.

    metastatic breast cancer

    phase 2 small molecule active

    1 trial

  5. A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

    Stemline Therapeutics B.V.

    Advanced ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  6. A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

    Stemline Therapeutics B.V.

    ​​Platinum-Resistant ovarian cancer​

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources